Podcasts about rory collins

Brian Kiley has made over 20 appearances on legendary shows like The Late Show with David Letterman, The Tonight Show, and Late Night with Conan O'Brien. He spent more than two decades as a staff writer for Conan, eventually becoming the head monologue writer earning 16 Emmy nominations and winning in 2007. He's also the author of The Astounding Misadventures of Rory Collins. It's been a pleasure to have him on the mat at Legacy in our early morning classes and to be able to sit down with him.Sponsored by TACFIT.com “The World's Smartest Workout” Açai Jungle Cafe “Your neighborhood Paradise” AcaiJungleCafe.com

Welcome to the Olink® Proteomics in Proximity podcast!   Below are some useful resources mentioned in this episode:  Olink tools and software·       Olink® Explore 3072, the platform utilized by the UK Biobank to measure ~3000 proteins in plasma: https://olink.com/products-services/explore/·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies  Press release and news story from UK Biobank:https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/launch-of-world-s-most-significant-protein-study-set-to-usher-in-new-understanding-for-medicine https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/dataset-of-thousands-of-proteins-marks-landmark-step-for-research-into-human-health https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies News stories:Today Programme – Professor Rory Collins live on programme, timestamp 02:36:37   Times – ‘Game-changing' study of blood proteins will help fight disease Independent – World's largest proteins study ‘invaluable' for understanding disease – experts Daily Mail – How Alzheimer's could be diagnosed a DECADE earlier following huge study of blood proteins Mirror – New blood test reveals risk of developing different diseases in 'new frontier of science' Science – Seeking disease insights, UK Biobank launches largest study of human proteinsTechnology Networks – UK Biobank Launches Largest Proteomics Study for Disease Research Chemical and Engineering News – Pharma firms team up to study UK proteomics data  Links to referred episodes:  • Evan – Episode 20:     https://share.transistor.fm/s/f795811e    https://open.spotify.com/episode/6lv5GA8hZCgDvujlBltS9f?si=36a29e6cfa4b4fae     https://podcasts.apple.com/us/podcast/how-proteomics-is-shaping-pharma-strategies/id1645900688?i=1000635040581 • Chris – Episode 16:     https://share.transistor.fm/s/255ad207     https://open.spotify.com/episode/0oe0S6zI8cryUtgZTjGlRq?si=8a7b0323b1364b96     https://podcasts.apple.com/us/podcast/interview-about-the-uk-biobank-with-dr-christopher-whelan/id1645900688?i=1000622521524  Subscribe to the podcast on your favorite player or app:Apple Podcasts: https://apple.co/3T0YbSm   Spotify Podcasts: https://open.spotify.com/show/2sZ2wxO...   Google Podcasts: https://podcasts.google.com/feed/aHR0...   Amazon Music:

Hang out with Al Mega as he chats with the man behind a sci-fi revolution in a groundbreaking biopunk comic, that is currently live on Kickstarter, Rory Collins. Tune in to learn all about this awesome new epic project and more… Support the Project at: https://www.kickstarter.com/projects/arks/arks-proximan-1 Follow on Social at: X: @ClickyW // Instagram:@clickysproutwife Website: www.clickysproutwife.com Episode 356 in an unlimited series! Host: Al Mega Follow on: Twitter | Instagram | Facebook): @TheRealAlMega / @ComicCrusaders Make sure to Like/Share/Subscribe if you haven't yet: https://www.youtube.com/c/comiccrusadersworld Twitch: https://www.twitch.tv/comiccrusaders Visit the official Comic Crusaders Comic Book Shop: comiccrusaders.shop Visit the OFFICIAL Comic Crusaders Swag Shop at: comiccrusaders.us Main Site: https://www.comiccrusaders.com/​​​​ Sister Site: http://www.undercovercapes.com​​​​ Pick up official Undercover Capes Podcast Network merchandise exclusively on RedBubble.com: bit.ly/UCPNMerch

This week, we're re-sharing one of our favorite episodes from the early days of The Genetics Podcast - one that many newer listeners may not have heard! Tune in as Professor Sir Rory Collins, Founder and Chief Executive of the UK Biobank, talks to us about the origins and evolution of this world-changing project that has catalysed a wave of new discoveries by levelling the playing field in data access. In this inspiring conversation, Professor Sir Rory Collins describes the ‘'If you build it, they will come get it” attitude of the UK Biobank. He believes that the pioneering and collaborative nature of UK Biobank means that the biggest impacts are yet to come. The conversation finishes with details on their COVID-19 work (as of 2020), which involved members from the original 500,000 strong UK Biobank cohort, as well as family members of these participants.

The incredible Brian Kiley is back this week as we share Part 2 of his great conversation with Mark and Lowell. Brian is one of the best and most well-respected TV comedy writers around. He's an Emmy award winner, and has written two fantastic books, "The Astounding Misadventures of Rory Collins" and "Maybe Kevin." This week Brian shares more insights into his experiences writing for both Conan and Ellen, how he crafts a comedy set, and his impressive regimen for being such a productive person. If you haven't already heard the first part, be sure to check out our past episodes to hear the first half of their conversation. If you're in the LA area on September 18 be sure to join Mark and Lowell for a live taping of the podcast at the world famous Hollywood Improv on Melrose! You can buy tickets here!Be sure to check out Mark's books:Available November 8, 2022."Why Not: Lessons on Comedy, Courage, and Chutzpah."Click on these links to buy:AmazonBarnes & NobleBooks-A-MillionBookshop.orgAnd read great road stories from some of the best comedians of our generation in Mark's first book  "I Killed: True Stories of the Road from America's Top Comics" available now!Please follow “You Don't Know Schiff” so you don't miss out on any exciting episodes. Click here to subscribe in Apple Podcasts (and please leave us 5 stars and a positive review - your support means the world to us and it helps us get discovered by new listeners):Your hosts:markschiff.comTwitter: @markschiffInstagram: markschiff1 Lowell BenjaminTwitter: @lowellcbenjaminInstagram: @lowellcbenjamin

Dawn and guest, Brian Kiley, were backstage at a comedy show when they first realized their shared love for History. In this episode, the two get to really let their nerd-flag fly and take turns sharing their favorite LOL moments from a wide variety of people, places and timelines. Prepare to feel (comparatively) less stupid in this episode devoted to History's Great Mistakes:00:04:40 - Before we dig deep in annals of history, we learn about Brian Kiley. How he first came to comedy, his Emmy nominations and wins for Conan O'Brien and Ellen - and how one prepares to make a 'last minute' appearance on Letterman. 00:10:43 - In addition to being a comedy writer, Brian Kiley is also a fiction-writer with two novels: The Astounding Misadventures of Rory Collins and Maybe Kevin.00:16:11 - Dawn finds herself in "nerd Paradise" as they prepare to jump in and swim around in the HILF of Great Mistakes.00:18:17 - Brian kicks things off with a hilarious and are-you-kidding-me nugget from our friends, the Pilgrims, and a certain 7' Native American. 00:20:54 - Dawn tells the story of The Children's Crusade - a tragically face-palming blip in the holy wars of Middle Ages in which a 12 year-old boy led over 30,000 children, on foot, across Europe to reclaim Jerusalem by slaying the enemy with their innocence... I know, right? 00:25:38 - It's Brian's turn and he brings us a moment featured in the movie THE RIGHT STUFF, in which astronaut John Glenn is temporarily mesmerized by brilliant otherworld particles in space... that turned out to be anything but. 00:27:33 - Dawn illustrates the ridiculous story of TULIP MANIA, when the Netherlands found themselves in the midst of the first economic bubble... but it was so pretty!BREAK00:33:22 - Before we jump back in, Dawn asks Brian if there is a comedian he can trace back to the origin of his interest in comedy, and he can:  Dick Gregory. 00:35:13 - Brian delivers the next LOL-HILF on his list, the hilarious story of the first hot-air ballon in France and the bizarre and yet totally predictable way that the people who see it react. 00:38:27 - In a one-two punch, Brian then tells the story of bright, yet unfortunate President Jimmy Carter and why his 2nd term seemed doomed to failure from the launch. 00:43:13 - It's Dawn's turn with a HILF of the worst building in London 'The Fryscraper' - and good/bad news - you can visit it to this day... and if you do, PLEASE SEND VIDEO. 00:48:57 - Brian was with his son in DC when he saw a misprinted headline from 1976 that suggested that two of the oldest, whitest, straightest guys in American politics just made-out in New Hampshire.00:52:00 - Wait til you hear what attempted presidential assassin, Squeaky Fromme, said as Gerald Ford's security took her down. 00:55:50 - Before I let him go, Brian delivers one more nugget about a presidential pet that would have been a welcome guest on HILF... if not a host. ---THANK YOU so much for listening. Please subscribe, share, rate & review us!LIVE RECORDING - May 26th, 2022 at The Glendale Reading Room in Glendale, CaliforniaNEXT EPISODE - EP17: Joan of Arc with Lauren Prichard. 

Theory and Practice speaks with Professor Sir Rory Collins, Head of Nuffield Department of Population Health at Oxford University and BHF (British Heart Foundation) Professor of Medicine and Epidemiology. Professor Collins is also Principal Investigator and Chief Executive of the UK Biobank.Relevant links:- Sir Rory Collins- Oxford University- British Heart Foundation- UK Biobank

Professor Sir Rory Collins, Founder and Chief Executive of the UK Biobank, talks to us this week about the origins of this world-changing project that has catalysed a wave of new discoveries in large part by levelling playing field in data access. In this inspiring conversation Professor Sir Rory Collins describes the 'if you build it, they will come' attitude of the UKBiobank, and how he believes the biggest impact from the UKBiobank is still to come. The conversation finishes with details on their COVID-19 work, which has involved not just members from the original 500,000 strong UKBiobank cohort, but also family members of these participants.

Professor Sir Rory Collins, Founder and Chief Executive of the UK Biobank, talks to us this week about the origins of this world-changing project that has catalysed a wave of new discoveries in large part by levelling playing field in data access. In this inspiring conversation Professor Sir Rory Collins describes the 'if you build it, they will come' attitude of the UKBiobank, and how he believes the biggest impact from the UKBiobank is still to come. The conversation finishes with details on their COVID-19 work, which has involved not just members from the original 500,000 strong UKBiobank cohort, but also family members of these participants.

Discussions of social determinants of health center on social programs as if they are equally available to everyone. The truth is, access to healthcare and social services is based on a punitive model that intentionally limits availability. So that’s what I dive into in this episode – here are the resources I mention: $1,000 a Month, No Strings Attached For Trans Women Silicone Pumping Can Be a Blessing and a Curse UK Biobank Requires Earth’s Geneticists to Cooperate, Not Compete Highlights include: 3:42 – “’Pumping’ refers to a kind of underground plastic surgery. Pumping is often turned to when licensed medicine isn’t accessible — typically because of a combination of social, financial and discriminatory barriers in health care.” Source: For Trans Women Silicone Pumping Can Be a Blessing and a Curse 5:30 – “Being able to pass as cisgender can, in some cases, be a matter of life and death.” Source: For Trans Women Silicone Pumping Can Be a Blessing and a Curse 5:54 – “Society defines who is worthy of health care, who is worthy of culturally competent care, who is worthy of even having access to health insurance,” Ruby Corado says. “And if you conform to [those] standards … then your privilege is that you can go to a doctor and get treated.” Source: For Trans Women Silicone Pumping Can Be a Blessing and a Curse 6:15 – JM: “It’s just pure luck whether we fall into a group where we get access to care or not.” 7:20 – JM: “We decide that some people are worth more and some people aren’t. It’s not random – it’s based on one group saying they want all the goodies and leaving all the other groups to scramble.” 10:03 – JM: “These judgments are more about the people making them than about the people receiving them.” 10:10 – “A nonprofit organization was looking to give 20 African American single mothers living in public housing $1,000 each month for a year. They’d be able to use the money in any way they pleased. … For decades, Republicans and Democrats alike have tried to push families out of poverty by adding restrictions to government welfare programs. There were work mandates, time limits, benefit caps — rules aimed at pointing families toward what the government thinks are good choices. Now, there is increasing interest in trying out the reverse.” Source: $1,000 a Month, No Strings Attached 11:30 – JM: “Think about how you would like it if someone tried to tell you how to spend your money. Or tried to tell you whether you were worth having a place to live. Think about how punitive our entire social welfare approach is. It’s all about ‘Are you worthy?’ of whatever the benefit is – and the benefit is so meager.” 12:07 – JM: “Hierarchies want the top to flourish and everybody else not to.” 13:25 – ““At the end of six months, none of the women reported using an emergency lender. Nearly all said they had enough money to buy school supplies, when fewer than half had said that before. They reported cooking more balanced meals, visiting the doctor and attending church more often. … ‘The beauty of all of this has just been how folks are light,’ Nyandoro said. ‘They aren’t walking around with the heaviness of life that, unfortunately, so many times low-income folks have to carry.’” Source: $1,000 a Month, No Strings Attached 14:43 – JM: “What if, we every time we wanted to add restrictions, we considered removing them, instead?” 16:09 – UK Biobank Chief Executive Dr. Rory Collins says, “The idea is to democratize research so scientists who might struggle to get funding and other resources can also make important contributions, using this dataset.” Source: UK Biobank Requires Earth’s Geneticists to Cooperate, Not Compete 16:25 – “(UK Biobank Chief scientist Dr. Cathie Sudlow) expects collaboration, rather than traditional competition, will be what really drives medical science forward.” Source: UK Biobank Requires Earth’s Geneticists to Cooperate, Not Compete 18:28 – JM: “How much of our society would be able to flourish if we stopped the judgment and stopped the restrictions and said, ‘What if we just gave you what you needed?'” 20:30 – JM: “It’s about making sure that women never feel adequate. And the result is that there is a huge amount of emotional energy that, instead of going to something we want, winds up going to this impossible and unnecessary task of changing our physical form.” 21:15 – JM: “What if we just had freedom to be beautiful the way we are?” 21:54 – JM: “What if we shook off all this baggage that we have been given that says we’re not worthy of even the most basic things, like being considered attractive or having a place to live or having food or being worthy of being listened to.” 23:27 – JM: “There is a difference between setting a boundary on something that has happened and is not being respectful of the gift that you’re giving and just restricting everything so that you’re not even allowing the other person to have the life that they deserve.” Leading with Health is the podcast where women dive into societal change through the lens of healthcare. Host Jennifer Michelle has a Master’s in Public Health and Epidemiology and is a certified EMT. As President of Michelle Marketing Strategies, Jennifer specializes in healthcare marketing. Jennifer is available to speak at conferences and also provides free marketing consultations. Contact her here.

In this episode of the podcast, hosted by Solange, Chris Bimson, Rory Collins, and Jorge Gueorguiev Garcia discuss The Craftsman's Oath by Robert C. Martin, also known as Uncle Bob Martin. Photo: Prairie Dog by DigiPD is licensed under CC0Music: "Sweeter Vermouth" by Kevin MacLeod is licensed under CC-BY 3.0

The women's and men's cross country teams both qualified for the NCAA Championships in the same year for the first time since 2012! Plus, we preview the basketball and swimming & diving seasons on the latest episode of the Bates Bobcast. Interviews this episode: 1:21 -- Bart Rust '22, Men's Cross Country (Male Bobcat of the Week) 8:52 -- Ayden Eickhoff '19, Women's Cross Country (Female Bobcat of the Week) 14:14 -- Alison Montgomery, Women's Basketball, Head Coach 22:01 -- Jon Furbush '05, Men's Basketball, Head Coach 28:42 -- Associate Head Coach Vanessa Williamson '05, Captains Catherine Mullen '19 and Rory Collins '19, Swimming and Diving

This podcast is an interview with Brian Kiley who is the author of, "The Astounding Misadventures of Rory Collins." Brian has been a staff writer for Conan O’Brien for 23 years and been nominated for 16 Emmy Awards one of which he won in 2007. He has appeared numerous times on the David Letterman show, Late Night with Conan and four times on the Tonight Show.

Emmy Award-winning writer Brian Kiley joins Nancy to discuss his early career from stand-up comedy and Late Night with Conan O’Brien, to his latest novel The Astounding Misadventures of Rory Collins. Read more in Nancy’s online column Showbiz Analysis for Parade Magazine.

Rory Collins discusses his Review of the evidence from randomised studies concerning the efficacy and safety of statins.

Brian Kiley is a stand-up, writer for Conan, and author of the book The Astounding Misadventures of Rory Collins.  Somehow, we haven't covered this album since our first three episodes, so it was definitely time for a revisit.  We sat down … Continue reading →

[intro music]   Hello, and welcome to Episode Twenty-two of Multiple Sclerosis Discovery, the podcast of the MS Discovery Forum. I’m your host, Dan Keller.   This week’s podcast features an interview with Dr. Paul Matthews about the Optimize project in the United Kingdom. But to begin, here’s a brief summary of some of the latest developments on the MS Discovery Forum at msdiscovery.org.   Some good news came from the pharmaceutical company Genzyme. On November 14th at 9 pm Eastern time, the FDA approved the drug alemtuzumab – trade name Lemtrada – for relapsing forms of MS. The FDA previously rejected the drug in 2013 due to concerns about study design and side effects. There is still some concern over safety, though, so the company is releasing it to only a limited number of patients. The prescription will also come with a host of other drugs to protect against harmful side effects. Researchers aren’t quite sure how the drug works, but it appears to target monocytes, T cells, and B cells.   Researchers announced a new mouse model for fatigue at the 2014 Society for Neuroscience meeting in Washington, D.C. The model works by enhancing expression of the pro-inflammatory cytokine, interleukin-1-beta. The model caused mice to reduce physical activity, without showing other signs of illness such as fever or anhedonia. Middle-aged and aged female mice were most affected by the treatment, whereas young mice showed no difference in signs of fatigue. The model gives credence to the idea that fatigue is not produced from dysfunction in the arousal system, but rather is a result of inflammation. The researchers said that they hoped the model will help illuminate the neurobiology of fatigue, the most common and debilitating symptom of MS.   If you would like to keep up with all things MSDF, please consider subscribing to our weekly newsletter. We keep our newsletter up-to-date with all of our news stories, blogs, and items from our professional and research resource sections. We’re also on Twitter; follow us at msdforum. And on Facebook, you can like us at facebook.com/ms discovery forum.   [transition music]   Now to the interview. Professor Paul Matthews is at Imperial College London in brain sciences. Last week he talked with MSDF about imaging in MS. This week we’re discussing his involvement in a UK-based project intended to optimize and personalize MS treatment.   Interviewer – Dan Keller Welcome, Professor Matthews. You’re participating in the Optimize project in the UK. Can you tell me about that?   Interviewee – Paul Matthews Well, thanks, Dan. Optimize has been an exciting journey and we’re still at the early stages, but let me tell you a little bit about it. Over three years ago, a number of us got together to discuss what the barriers to development of stratified or personalized medicine for multiple sclerosis was. We all recognized what the potential could be if we could really figure out how to target medicines to responders, we would have a way of most appropriately staging the introduction of different medicines across patient populations, not exposing people who didn’t need them to drugs of higher risk and insuring that those who did need them got them early. This is a particular problem in the United Kingdom where there is a much more formal process for progressing from first-line DMTs to more powerful agents. And, in fact, there’s also – dare I say it – I mean, a frank therapeutic nihilism and a surprisingly small number of MS patients receive treatment because of the perceived lack of benefit to many of these first-line therapies.   Now how to change this. I think what we realized is that we need to have much more granular data on the characteristics of patients being treated and how they fared after their treatment over the long-term. The data provided within the usual clinical context is not only limited, but it ends up being rather patchy over time. In order to enable that, we needed tools that would both collect data and incentivize collection of complete data of high quality. Now a note about this. We all know how to do this within the context of clinical trials, but it’s hugely expensive; it’s expensive because there are multiple people always involved to crosscheck that the data is completely acquired in each paper, and secondarily, there are audit procedures in place in retrospect to insure that this is being done. This really isn’t feasible in routine clinical practice.   A colleague of mine, Rory Collins, who has specialized in setting up very large-scale clinical trials in areas like China and India, has shown how very simple electronic tools can help both insure that data is acquired completely and that there is an electronic audit trail to follow-up on data that isn’t. What they showed is that by creating simple electronic questionnaires that wouldn’t let the questionnaire be closed unless data of an appropriate type was entered in the field, and then automatically interrogating the data for quality from center to center and following up where there were potential lapses, one could begin to incentivize acquisition of the right data and actually make it flow faster.   So how could we make this happen within the MS space in the UK? Well, what we realized is that the toolkits were all there. The EU IMI program already has funded my colleague, Yike Guo, who’s head of the Imperial College Data Science Institute, to create a tool built around a platform called eTRIKS. This is a data management environment that allows links to apps or iPads or any other peripheral electronic tool for very powerful distributed data capture. We then, in gathering together a number of stakeholder meetings which involved people with MS, the MS societies, a number of industry representatives, and what I’m really pleased to say is leads from fully 18 of the major MS centers across the United Kingdom pretty much ringing the country, together created the vision of building such an electronic tool, distributing the types of input devices across the different centers, and beginning to create a database that could be held centrally or in a distributed fashion using all the new tricks of modern IT.   The first thing is acquiring the data, the second is doing useful with it. The second thing that’s rather neat about the eTRIKS platform is that we have shown how it can be built to allow different levels of access, so that there can be access by high-level users who get to see the whole dataset, but also by specialized users who might want to see only a part of it – like a doctor interrogating it for his or her patient – or, importantly, a person with MS interrogating it to see how the data that they have entered stands relative to that that’s entered across the country by all patients; it allows people with MS to begin to gauge how they’re doing relative to others with their disease.   Now, I think the latter point is worth building on, because I think all of us have been hugely impressed by the power of sites like Patients Like Me to engage people with the disease in the dialog about their disease and make them full participants in capturing data information. With this kind of distributed data platform where doctors and people with MS can enter data whenever and wherever they are to a central database which can organize it and allow it then to be interrogated as needed, means that we can begin to think about asking patients to enter data on the fly from home. Why is this important? Well, this actually completely transforms the way in which we understand the disease, it really gives us a much deeper sense of the patient experience. Rather than sampling a patient once every month or once every six months, we can actually capture how they’re doing through a day. And if we add to this some extra sensor technologies – say, for example, about movement – we can literally do this from moment to moment.   So the vision thus is that if we can use these modern IT tools to capture data from distributed sources – from doctors using iPads, from patients using apps, from sensors that people with MS wear – we can capture data in a central resource that can be distributed to those for the purposes that they need it in near real-time, and in turn provide a common environment for its analysis. I think it’s exciting. Now we’re at the early stages, the basic tools have been designed, we’re starting to build the sensor technology. And our genuine hope is with the completion of the first set of agreements with one of the companies who’s been the first to really take a plunge with us, we’re going to be able to create a beta form of the tool in 6-9 months.   Now before closing, I do want to add one thing. This is an exciting vision but the notion of building a database is hardly a new one and many people have had it. There is something that’s special about this vision and it’s the thing that I’m most proud of that’s come together from all of these stakeholders. It’s the vision of creating a database that will be an open database; open to all researchers once it’s built, not held privately by those who built it. And I think this is what could become a game-changer. Moreover, we see that the tools that we’re building in order to create this – the IT tools, the distributed apps, and so on – are tools that the community should own and should be able to improve on. So our intention is fully, as this program develops, to release a software for open-access use as well as the data. Our hope is that even if this doesn’t provide the solution of the future, it will begin to incentivize this kind of practice where we all share this important data to work together to find solutions to this disease.   MSDF Besides collecting MS-specific data, will it also look at general health and comorbidities to see how that affects outcomes?   Dr. Matthews No. That’s a really good question. Like so many doctors now, we’re very much focused on the progressive forms of the disease. Our belief is that comorbidities make major contributions to this, and that by influencing these comorbidities we may have the biggest short-term impact on our patients’ lives. So one of the advantages of a big data capture tool is that we can capture data on all of the other disorders that afflict people with MS, as well, and begin with, again, greater granularity because of contributions from people with as well as their doctors to look at this in ways that wonderful databases like NARCOMS haven’t been able to do. This is an important task for the future and one that we really want to grasp. We’re hoping with further funding to be able to link this to bioresources, as well, and the ability to access a patient’s fluid samples for Omics analyses certainly can add greatly to this.   MSDF Very good, I appreciate it.   Dr. Matthews You’re welcome, Dan, it’s been good speaking to you.   [transition music]   Thank you for listening to Episode Twenty-two of Multiple Sclerosis Discovery. This podcast was produced by the MS Discovery Forum, MSDF, the premier source of independent news and information on MS research. MSDF’s executive editor is Robert Finn. Msdiscovery.org is part of the non-profit Accelerated Cure Project for Multiple Sclerosis. Robert McBurney is our President and CEO, and Hollie Schmidt is vice president of scientific operations.   Msdiscovery.org aims to focus attention on what is known and not yet known about the causes of MS and related conditions, their pathological mechanisms, and potential ways to intervene. By communicating this information in a way that builds bridges among different disciplines, we hope to open new routes toward significant clinical advances.   We’re interested in your opinions. Please join the discussion on one of our online forums or send comments, criticisms, and suggestions to editor@msdiscovery.org.    [outro music]  

Keith Fox, president of the British Cardiovascular Society, and Rory Collins, co-director of the University of Oxford's Clinical Trial Service Unit and Epidemiological Studies Unit, discuss the safety of statins, and how clever prescribing can overcome worries about myopathy. Also this week, Tony Delamothe, BMJ deputy editor, explains why the sudden interest in atrial fibrillation is making him queasy.

Where are we now with changing cholesterol levels to reduce cardiovascular disease risk? Keith Fox (British Cardiovascular Society president) asks Rory Collins (professor of Medicine and Epidemiology and co-director of the Clinical Trial Service, Nuffield Department of Clinical Medicine, University of Oxford).Professor Collins talks about the evidence behind altering high- and low-density lipoproteins, why the issue of myopathy has been overstated, and our best treatment options now and for the future.See also:Webcasts from all the sessions at the British Cardiovascular Society Conference 2012 http://bit.ly/ZMGmUE